<DOC>
	<DOC>NCT00683878</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied</brief_summary>
	<brief_title>Add-on to Thiazolidinedione (TZD) Failures</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Males and females, ≥ 18 years old, with type 2 diabetes and with inadequate glycemic control All subjects must have central laboratory prerandomization A1C ≥ 7.0 and ≤ 10.5% Cpeptide ≥ 1.0 ng/mL (0.34 nmol/L) Body Mass Index ≤ 45.0 kg/m² AST and /or ALT &gt; 2.5 times the upper limit of normal Serum total bilirubin &gt; 2 mg/dL (34.2 µmol/L) Creatinine kinase &gt; 3.0 times the upper limit of normal Symptoms of severely uncontrolled diabetes Serum creatinine ≥ 2.0 mg/dL Calculated CrClearance &lt; 50 ml/min (calculated by CockroftGault formula) Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>